Lynch syndrome, historically known as hereditary non-polyposis colorectal cancer, affects roughly 1 in 279 people globally and is caused by inherited, pathogenic variants in one of the DNA mismatch repair genes—MLH1, MSH2, MSH6 or PMS2—or in the EPCAM gene, whose deletions silence MSH2. These genes encode the cellular machinery that proofreads DNA during replication; when one copy is inherited in a damaged form, a single “second hit” in a somatic cell is enough to cripple repair entirely, allowing mutations to accumulate at breathtaking speed. The result is a dramatically elevated lifetime risk of colorectal and endometrial cancers, along with elevated risks of tumors of the stomach, ovary, urinary tract, small bowel, pancreas, biliary tract, skin and brain. Mismatch-repair-deficient tumors are characterized by microsatellite instability and high tumor mutational burden, molecular signatures that shape both diagnosis and therapy.

The patient’s story began in April 2014, when she presented with abdominal discomfort, iron deficiency anemia and stool occult blood against a family history dense with colorectal cancer that met both the Bethesda and Amsterdam clinical criteria. Colonoscopy revealed a mass in the ascending colon, and she underwent a total colectomy with proximal proctectomy, ileorectal anastomosis and lymph node dissection. Pathology showed a 6-centimeter, low-grade, mucin-producing adenocarcinoma staged pT3N0. Immunohistochemistry demonstrated complete loss of the MLH1 and PMS2 proteins, and polymerase chain reaction testing with the Bethesda panel confirmed high-level microsatellite instability. Critically, the team then performed pyrosequencing on formalin-fixed tissue to exclude the sporadic route to mismatch repair deficiency: MLH1 promoter methylation was absent and BRAF V600E was wild-type, pointing strongly toward an inherited defect rather than an acquired one.

Germline panel testing subsequently identified the c.131C>A (p.Ser44Tyr) variant in the MLH1 gene. At the time of testing in 2017, the variant was classified as a variant of uncertain significance, but the accumulated clinical, histopathological and molecular evidence was sufficient to diagnose Lynch syndrome and enroll the patient in active surveillance. The evidence base for the variant matured quickly: pathogenicity data submitted to the Leiden Open Variation Database supported reclassification, and by 2018 p.Ser44Tyr was formally designated pathogenic, confirming the diagnosis. She received six months of adjuvant XELOX chemotherapy, a decision made in 2014 before current guidelines—which favor observation alone for deficient mismatch repair stage II colon cancer—were fully established, owing to her young age and extensive family history.

For seven years she remained symptom-free. Then, at age 36 in August 2021, pruritus and a sharply elevated alkaline phosphatase of 1091 signaled biliary obstruction. Ultrasound and contrast-enhanced computed tomography revealed a 23 by 24 by 27 millimeter mass in the head of the pancreas compressing the common bile duct, without invasion of the superior mesenteric artery. Endoscopic ultrasound-guided fine-needle aspiration of the mass and a hilar lymph node yielded a well-differentiated neuroendocrine neoplasm. Immunostaining showed diffuse synaptophysin positivity, focal chromogranin A expression and a Ki-67 proliferation index of 5 percent—a Grade 2 pancreatic neuroendocrine tumor under the WHO 2019 classification. She underwent a Whipple procedure, and the resected specimen confirmed a 2.7-centimeter Grade 2 tumor with peripancreatic soft tissue extension and 28 negative lymph nodes.

The molecular bombshell came from the resected pancreatic tumor itself: immunohistochemistry demonstrated loss of MLH1 and PMS2 expression within the neuroendocrine cells, an extraordinarily unusual finding in this tumor type. The result was verified by an independent second laboratory, establishing the tumor as genuinely mismatch-repair-deficient and arising in the context of Lynch syndrome. A literature review by the case authors identified only three previously reported pancreatic neuroendocrine tumors in Lynch syndrome patients, none of them metastatic, making this young woman’s presentation the first documented case of an intermediate-grade, deficient-repair pancreatic neuroendocrine tumor with confirmed liver metastases in this population. For context, mismatch repair carriers face roughly a 6.2 percent lifetime pancreatic cancer risk through age 80, versus 1.6 percent in the general population—but those malignancies are almost always ductal adenocarcinomas, not neuroendocrine tumors.

Surveillance followed the North American and European Neuroendocrine Tumor Society guidelines, with contrast-enhanced multiphasic MRI every six months. When subtle hepatic changes appeared on postoperative ultrasound, the team escalated to gallium-68 DOTATATE positron emission tomography at six months post-resection—a deviation from routine surveillance justified by the high-risk context. The functional scan, which exploits the dense somatostatin receptors that neuroendocrine tumors display on their surfaces, revealed multiple liver lesions across both lobes plus mesenteric soft tissue enhancement, highly suggestive of metastatic disease. Core needle biopsy of a hepatic lesion confirmed a well-differentiated Grade 1 metastatic neuroendocrine tumor with a Ki-67 index of just 1 percent.

Then came the twist. Immunohistochemistry on the liver metastasis showed intact—retained—MLH1 and PMS2 expression, directly contradicting the complete loss seen in the pancreatic primary. To resolve whether the two tumors were even related, the team performed next-generation sequencing on tissue from both sites using a comprehensive cancer panel. The sequencing confirmed the identical germline MLH1 c.131C>A variant in both lesions, establishing a clonal relationship, while revealing discordant somatic mutational profiles—each tumor had accumulated its own distinct additional alterations. No MLH1 reversion mutations were found in the metastasis. The authors propose several mechanisms: subclonal selection during metastatic dissemination may have favored clones that retained functional mismatch repair through epigenetic modification; the “second hit” disabling the wild-type MLH1 allele may have operated differently at the primary versus metastatic site; or the liver microenvironment’s immune surveillance and metabolic pressures may have selected for clones with intact DNA repair.

These findings directly shaped therapy. Although immune checkpoint blockade with pembrolizumab has transformed care for mismatch-repair-deficient solid tumors, well-differentiated neuroendocrine tumors typically harbor immunologically “cold” microenvironments, and—most decisively—the actual therapeutic target, the metastatic disease, had intact repair machinery and would likely not respond to checkpoint inhibitors. The multidisciplinary tumor board instead followed neuroendocrine tumor consensus guidelines, starting octreotide LAR at 30 milligrams every 28 days, a somatostatin analog appropriate for an asymptomatic patient with low tumor burden and low proliferative index. At three-month follow-up in June 2022, imaging documented progression under RECIST 1.1 criteria—a 35 percent increase in the sum of target lesions plus new hepatic lesions—prompting escalation to peptide receptor radionuclide therapy with lutetium-177 vipivotide tetraxetan (Lutathera) at 7.4 gigabecquerels every 8 weeks for four cycles, with octreotide continued between infusions.

The outcome has been remarkable. The patient has maintained durable disease control for more than three years, remaining clinically well and symptom-free, with serial gallium-68 DOTATATE scans showing the liver lesions shrinking steadily across 12- and 18-month follow-up imaging. She now undergoes positron emission tomography surveillance every six months. The case authors emphasize several broader lessons: Lynch syndrome surveillance may warrant expansion beyond the traditional colorectal and endometrial focus in high-risk individuals, hereditary cancer registries should systematically capture atypical tumor presentations to refine genotype-phenotype correlations, and comprehensive molecular profiling—including immunohistochemistry, microsatellite instability testing, promoter methylation analysis, BRAF genotyping and paired next-generation sequencing of primary and metastatic lesions—is indispensable when hereditary cancer syndromes produce unexpected tumors. As metachronous malignancies continue to emerge in Lynch syndrome carriers decades after their first diagnoses, this single patient’s journey from colectomy to Whipple procedure to radioligand therapy illustrates both the power and the unfinished questions of precision oncology—particularly the enigma of why two tumors from the same founding clone can look, behave and respond so differently.

Lynch Syndrome arises from germline mutations in DNA mismatch repair (MMR) genes, which are crucial for maintaining genomic integrity. The defective DNA repair mechanisms in LS carriers often lead to microsatellite instability (MSI), characterized by the insertion or deletion of short repetitive DNA sequences. This genomic instability fuels the generation of tumor-specific neoantigens—novel peptide sequences resulting from these mutation events that are presented on the surfaces of cancer cells. Importantly, these neoantigens serve as flags for the immune system, particularly for T cells, which orchestrate targeted cytotoxic responses against aberrant cells.

The research team applied high-throughput sequencing technology to analyze the TCR repertoires within peripheral blood mononuclear cells (PBMCs), which harbor the T cell populations integral to adaptive immunity. Sampling 277 individuals—including 102 LS cancer survivors, 130 LS carriers without cancer (often referred to as “previvors”), and 45 controls without LS or cancer—the investigators generated comprehensive TCR profiles. By comparing these immune landscapes, they sought to delineate patterns characteristic of LS carriers irrespective of their disease state.

Crucially, in parallel tissue analyses involving colorectal tumor and precancerous samples matched to blood specimens, the scientists identified clonal expansions of T cells defined by their TCR sequences uniquely reactive to tumor-associated neoantigens. Up to 41% of these TCR clones found in colon lesions were detectable in the blood of LS carriers alone, suggesting a vigilant systemic immune surveillance mechanism operational well before overt malignancy manifests. This finding challenges traditional paradigms of cancer development by highlighting the immune system’s ongoing engagement with nascent tumorigenic processes.

Leveraging these insights, the research team developed a sophisticated classification model that meticulously distinguishes LS carriers from non-carriers purely based on circulating TCR profiles. Remarkably, this model performed effectively regardless of whether the LS individual had an existing cancer diagnosis, thereby offering a powerful prognostic tool for preemptive risk stratification. Such non-invasive biomarker assays could revolutionize screening protocols by enabling early intervention tailored to an individual’s immunogenetic risk.

The implications of this research are profound. By harnessing the specificity of adaptive immune responses encoded in TCR repertoires, clinicians may soon utilize blood tests to monitor immune dynamics and cancer risk longitudinally in genetically predisposed populations. This approach circumvents the limitations of conventional screening modalities, reducing patient burden and allowing for more frequent and personalized assessments. The dynamic nature of the immune signatures also holds promise for monitoring responses to immunopreventive and therapeutic strategies.

Furthermore, the study augments our understanding of the intricate interplay between tumor evolution and host immunity in Lynch Syndrome carriers. It underscores the potential of T cell receptor sequencing as a functional readout of tumor-immune interactions at the molecular level. By deciphering the immunogenomic landscape preemptively, researchers can not only flag individuals at imminent risk but also gain mechanistic insights to inform development of vaccines and immune-modulating therapies aimed at intercepting cancer at its earliest stages.

The utilization of peripheral blood as the sampling medium enhances the translational feasibility of this technology. Blood draws are minimally invasive, cost-effective, and readily repeatable, making them ideal for large-scale population screening and dynamic disease monitoring. The discovery that tumor-specific immune signatures are reflected systemically negates the need for invasive biopsies and opens new frontiers in early cancer diagnostics.

However, despite the promising results, additional validation in larger, independent cohorts remains essential to refine the sensitivity and specificity of the TCR-based classifier. Longitudinal studies are also warranted to assess how these immune signatures evolve over time, especially in response to environmental exposures, lifestyle factors, and preventative interventions. Such comprehensive datasets will be vital for integrating this biomarker into routine clinical workflows.

Dr. Eduardo Vilar-Sanchez emphasized the transformative potential of this research, remarking that a non-invasive blood test to surveil cancer risk and immune activity represents a monumental advance for individuals with Lynch Syndrome. This biomarker platform offers clinicians unprecedented tools to personalize prevention strategies, optimize surveillance intervals, and potentially delay or avert cancer onset through immunological insights.

Overall, this pioneering work exemplifies the convergence of genomics, immunology, and precision medicine, highlighting how elucidating the adaptive immune repertoire can unlock novel pathways for cancer interception. As Lynch Syndrome affects a significant subset of the population with hereditary cancer risk, innovations like this blood-based TCR biomarker signify hope for reducing morbidity and mortality through earlier diagnosis and individualized care.

The study’s multidisciplinary design, encompassing molecular genetics, immunological profiling, and computational modeling, sets a new standard for biomarker discovery. It inspires future research exploring the broader applicability of TCR repertoire analyses across diverse cancer predispositions and other immune-mediated diseases. By deepening our knowledge of immune surveillance mechanisms in hereditary cancer syndromes, this research paves the way for a new era of immunogenomic diagnostics.

In conclusion, the identification of circulating tumor-reactive T cell receptors in Lynch Syndrome carriers offers a pioneering platform for early cancer detection and personalized risk evaluation. This innovative blood test, pending further validation, could transform clinical practice by facilitating timely interventions based not solely on genetic predisposition but also on dynamic immune monitoring, potentially saving countless lives in the process.

Subject of Research: Lynch Syndrome, T cell receptor sequencing, early cancer detection, immune biomarkers

Article Title: Researchers Identify Circulating T Cell Receptor Signatures as Blood-Based Biomarkers for Lynch Syndrome Cancer Risk

News Publication Date: April 6, 2026

Web References:

• MD Anderson Cancer Center
• Lynch Syndrome Information
• Microsatellite Instability (MSI)
• Nature Communications Article

Keywords: Lynch Syndrome, DNA mismatch repair, T cell receptor sequencing, microsatellite instability, colorectal cancer, endometrial cancer, tumor neoantigens, immune surveillance, blood biomarker, early cancer detection, adaptive immune response, precision oncology